Literature DB >> 22925378

ICRP publication 118: ICRP statement on tissue reactions and early and late effects of radiation in normal tissues and organs--threshold doses for tissue reactions in a radiation protection context.

F A Stewart, A V Akleyev, M Hauer-Jensen, J H Hendry, N J Kleiman, T J Macvittie, B M Aleman, A B Edgar, K Mabuchi, C R Muirhead, R E Shore, W H Wallace.   

Abstract

This report provides a review of early and late effects of radiation in normal tissues and organs with respect to radiation protection. It was instigated following a recommendation in Publication 103 (ICRP, 2007), and it provides updated estimates of 'practical' threshold doses for tissue injury defined at the level of 1% incidence. Estimates are given for morbidity and mortality endpoints in all organ systems following acute, fractionated, or chronic exposure. The organ systems comprise the haematopoietic, immune, reproductive, circulatory, respiratory, musculoskeletal, endocrine, and nervous systems; the digestive and urinary tracts; the skin; and the eye. Particular attention is paid to circulatory disease and cataracts because of recent evidence of higher incidences of injury than expected after lower doses; hence, threshold doses appear to be lower than previously considered. This is largely because of the increasing incidences with increasing times after exposure. In the context of protection, it is the threshold doses for very long follow-up times that are the most relevant for workers and the public; for example, the atomic bomb survivors with 40-50years of follow-up. Radiotherapy data generally apply for shorter follow-up times because of competing causes of death in cancer patients, and hence the risks of radiation-induced circulatory disease at those earlier times are lower. A variety of biological response modifiers have been used to help reduce late reactions in many tissues. These include antioxidants, radical scavengers, inhibitors of apoptosis, anti-inflammatory drugs, angiotensin-converting enzyme inhibitors, growth factors, and cytokines. In many cases, these give dose modification factors of 1.1-1.2, and in a few cases 1.5-2, indicating the potential for increasing threshold doses in known exposure cases. In contrast, there are agents that enhance radiation responses, notably other cytotoxic agents such as antimetabolites, alkylating agents, anti-angiogenic drugs, and antibiotics, as well as genetic and comorbidity factors. Most tissues show a sparing effect of dose fractionation, so that total doses for a given endpoint are higher if the dose is fractionated rather than when given as a single dose. However, for reactions manifesting very late after low total doses, particularly for cataracts and circulatory disease, it appears that the rate of dose delivery does not modify the low incidence. This implies that the injury in these cases and at these low dose levels is caused by single-hit irreparable-type events. For these two tissues, a threshold dose of 0.5Gy is proposed herein for practical purposes, irrespective of the rate of dose delivery, and future studies may elucidate this judgement further.
Copyright © 2012. Published by Elsevier Ltd.

Entities:  

Mesh:

Year:  2012        PMID: 22925378     DOI: 10.1016/j.icrp.2012.02.001

Source DB:  PubMed          Journal:  Ann ICRP        ISSN: 0146-6453


  245 in total

Review 1.  A New Era of Low-Dose Radiation Epidemiology.

Authors:  Cari M Kitahara; Martha S Linet; Preetha Rajaraman; Estelle Ntowe; Amy Berrington de González
Journal:  Curr Environ Health Rep       Date:  2015-09

2.  Circulatory disease mortality in the Massachusetts tuberculosis fluoroscopy cohort study.

Authors:  Mark P Little; Lydia B Zablotska; Alina V Brenner; Steven E Lipshultz
Journal:  Eur J Epidemiol       Date:  2015-08-09       Impact factor: 8.082

3.  Organ and effective dose reduction for region-of-interest (ROI) CBCT and fluoroscopy.

Authors:  Zhenyu Xiong; Sarath Vijayan; Stephen Rudin; Daniel R Bednarek
Journal:  Proc SPIE Int Soc Opt Eng       Date:  2017-03-09

4.  Influence of eye size and beam entry angle on dose to non-targeted tissues of the eye during stereotactic x-ray radiosurgery of AMD.

Authors:  Justin L Cantley; Justin Hanlon; Erik Chell; Choonsik Lee; W Clay Smith; Wesley E Bolch
Journal:  Phys Med Biol       Date:  2013-09-12       Impact factor: 3.609

5.  Dentofacial parameters explaining variability in retroclination of the maxillary central incisors.

Authors:  Bernd G Lapatki; Andreas Klatt; Jürgen Schulte-Mönting; Irmtrud E Jonas
Journal:  J Orofac Orthop       Date:  2007-03       Impact factor: 1.938

6.  Reply to "On the low-dose radiation exposure in the Techa River Cohort and mortality from circulatory diseases" by Jargin (2013).

Authors:  L Yu Krestinina; A V Akleyev
Journal:  Radiat Environ Biophys       Date:  2013-06-04       Impact factor: 1.925

Review 7.  A review of non-cancer effects, especially circulatory and ocular diseases.

Authors:  Mark P Little
Journal:  Radiat Environ Biophys       Date:  2013-08-01       Impact factor: 1.925

8.  Different Sequences of Fractionated Low-Dose Proton and Single Iron-Radiation-Induced Divergent Biological Responses in the Heart.

Authors:  Sharath P Sasi; Xinhua Yan; Marian Zuriaga-Herrero; Hannah Gee; Juyong Lee; Raman Mehrzad; Jin Song; Jillian Onufrak; James Morgan; Heiko Enderling; Kenneth Walsh; Raj Kishore; David A Goukassian
Journal:  Radiat Res       Date:  2017-06-14       Impact factor: 2.841

9.  Radiation doses to operators performing transjugular intrahepatic portosystemic shunt using a flat-panel detector-based system and ultrasound guidance for portal vein targeting.

Authors:  Roberto Miraglia; Roberta Gerasia; Luigi Maruzzelli; Mario D'Amico; Angelo Luca
Journal:  Eur Radiol       Date:  2016-08-25       Impact factor: 5.315

Review 10.  Cardiovascular sequelae of radiation therapy.

Authors:  Francesco Santoro; Nicola Tarantino; Pier Luigi Pellegrino; Marica Caivano; Agostino Lopizzo; Matteo Di Biase; Natale Daniele Brunetti
Journal:  Clin Res Cardiol       Date:  2014-05-07       Impact factor: 5.460

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.